With preparations underway for a possible vaccine-rollout by January, the Indian drug regulator is looking at the United Kingdom before deciding on giving emergency use authorization to the Serum Institute that is manufacturing the shots here. Sources believe that the U.K. may give its nod to the Oxford Covid-19 vaccine next week.
Once the U.K. drug regulator gives its approval to the Oxford vaccine, the expert committee on Covid-19 at the CDSCO will hold its meeting and thoroughly review the safety and immunogenicity data from the clinical evaluations conducted abroad and in India before granting any emergency authorization for the vaccine here, official sources said.
The process of granting emergency use approval for Bharat Biotech’s COVID-19 vaccine ‘Covaxin’ may take time as its phase 3 trials are still underway, while Pfizer is yet to make a presentation. “Going by this, Oxford vaccine ‘Covishield’ is likely to be the first to be rolled out in India,” a source said.
Serum Institute of India (SII)last week also had submitted some additional data required by the Drug Controller General of India (DCGI), the sources said. Amid fears about the mutated variant of SARS-CoV-2 detected in the UK, government officials recently said that it will have no impact on the potential of emerging vaccines that are being developed in India and other countries.The application by the Indian arm of US pharmaceutical firm Pfizer was not taken up for deliberation as the company had sought more time for making a presentation before the committee. The Pfizer vaccine has already been approved by several countries including the UK, the US, and Bahrain.The Pune-based SII, the world’slargestvaccine manufacturer, has made a collaboration with the University of Oxford and AstraZeneca to manufacture the vaccine. The SII has already manufactured 40 million doses of the vaccine, under the at-risk manufacturing and stockpiling licence from the DCGI, officials recently had said.
While considering SII’s application, the SEC had recommended that the firm should submit an updated safety data of phase 2 and 3 clinical trials in the country, immunogenicity data from the clinical trial in the UK and India, along with the outcome of the assessment of the UK Medicines and Healthcare products Regulatory Agency (MHRA) for grant of EUA. As for Hyderabad-based Bharat Biotech, “after detailed deliberation, the committee recommended that the firm should present the safety and efficacy data from the ongoing phase 3 clinical trial in the country for further consideration”, the SEC had said.
- 1,500 Oxford Vaccine Trial Volunteers Given Wrong Dose, Kept In Dark About Error - February 2, 2021
- Kangana Ranaut Summoned By Mumbai Court In Javed Akhtar Defamation Case - February 2, 2021
- Iron bars hooked between barriers, cement poured in to create makeshift wall at Singhu border - February 2, 2021